Studying zuranolone for postpartum depression after pregnancy
Treatments studied
Part of Mental health, Women’s health & pregnancy clinical trials.
This study looks at how the medicine zuranolone (taken for postpartum depression) works in real life for people who got a prescription within a year after their pregnancy ended. Researchers want to see if symptoms improve and how participants feel while taking it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult who was prescribed zuranolone for postpartum depression within the last year after your pregnancy ended.
- You have filled your zuranolone prescription at least once (and taken it for the first time) between June 2025 and May 2026.
- You currently live in the United States.
- You have not taken zuranolone or brexanolone in the past 12 months before this study.
- You do not have a current or past diagnosis of bipolar disorder.
- You have taken 1 or fewer doses of zuranolone so far (have not yet taken two or more doses).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how people with postpartum depression feel over time after starting zuranolone. It uses simple questionnaires to track changes in symptoms.
This trial tests whether allopregnanolone, a natural brain chemical, can help depression in women going through menopause. It compares the effects against a placebo to see if it improves mood symptoms.
This trial tests a new medicine called zuranolone (allopregnanolone) for people with depression after a stroke. It aims to see if the drug can help improve mood when taken over a short period.
This study compares two medications, quetiapine and trazodone, to see which works better for women with postpartum depression. You take one of them for about 8 weeks, and the team checks your mood and side effects.
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
This trial studies a natural brain chemical called allopregnanolone in women with premenstrual dysphoric disorder (PMDD) that responds to SSRI antidepressants. It aims to understand how the brain adapts and whether this treatment could help.
Hear when a new Depression, Postpartum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.